Double variants in TSHR and DUOX2 in a patient with hypothyroidism: case report by Sasivari, Zerin et al.








Double variants in TSHR and DUOX2 in a patient with hypothyroidism:
case report
Sasivari, Zerin ; Szinnai, Gabor ; Seebauer, Britta ; Konrad, Daniel ; Lang-Muritano, Mariarosaria
Abstract: Thyroid dyshormonogenesis (TDH) is characterized by the defective synthesis of thyroid hor-
mones. We present a patient with congenital hypothyroidism (CH) who presented in newborn screening
with elevated serum thyroid-stimulating hormone (TSH), decreased free thyroxine (fT<jats:sub>4</jats:sub>)
and increased thyroglobulin (Tg) concentrations. Ultrasound scan revealed a properly structured thyroid
gland. Treatment with L-thyroxine was initiated. At the age of 2 years, thyroxine replacement was
stopped. The patient remained untreated until 6 years of age when TSH levels progressively increased
and L-thyroxine treatment was restarted at a dose of 12.5 ฀g/day. Genetic analysis revealed a double
heterozygosity for likely pathogenic variants of dual oxidase 2 (<jats:italic>DUOX2</jats:italic>) and
thyroid stimulating hormone receptor <jats:italic>(TSHR</jats:italic>). Both genes were earlier shown
to be associated with CH. In a literature review, our patient was compared to previously published
patients with similar clinical characteristics, and a good genotype-phenotype correlation was identified.
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Abstract: Thyroid dyshormonogenesis (TDH) is charac-
terized by the defective synthesis of thyroid hormones. 
We present a patient with congenital hypothyroidism 
(CH) who presented in newborn screening with elevated 
serum thyroid-stimulating hormone (TSH), decreased free 
thyroxine (fT
4
) and increased thyroglobulin (Tg) concen-
trations. Ultrasound scan revealed a properly structured 
thyroid gland. Treatment with L-thyroxine was initiated. 
At the age of 2 years, thyroxine replacement was stopped. 
The patient remained untreated until 6 years of age when 
TSH levels progressively increased and L-thyroxine treat-
ment was restarted at a dose of 12.5 µg/day. Genetic 
analysis revealed a double heterozygosity for likely path-
ogenic variants of dual oxidase 2 (DUOX2) and thyroid 
stimulating hormone receptor (TSHR). Both genes were 
earlier shown to be associated with CH. In a literature 
review, our patient was compared to previously published 
patients with similar clinical characteristics, and a good 
 genotype-phenotype correlation was identified.
Keywords: congenital hypothyroidism; DUOX2 variant; 
TSHR variant.
Introduction
Congenital hypothyroidism (CH) occurs with an incidence 
of 1:3000–1:4000 [1]. Neonatal screening for CH was intro-
duced in Switzerland in 1977 to prevent mental retardation 
in affected newborns [2]. Newborn screening in Swit-
zerland determines thyroid-stimulating hormone (TSH) 
but not thyroxine (T
4
) concentration. Thus, newborns 
with central or secondary hypothyroidism are missed in 
Switzerland.
Primary CH can be classified into two forms: thyroid 
dysgenesis, which accounts for approximately 80–85% of 
all cases with permanent primary CH including resistance 
to TSH, and thyroid dyshormonogenesis (TDH), account-
ing for 10–15% of cases. Thyroid dysgenesis is caused by 
disordered development of the thyroid gland and results 
in athyreosis, hypoplastic or ectopic thyroid gland. TSH 
resistance can cause hypoplastic or normally sized thyroid 
gland. TDH is characterized by eutopic thyroid gland of 
normal size, or goiter [1].
Most forms of TDH are transmitted autosomal reces-
sively and so far variants in seven different genes coding 
for the following proteins have been identified: thyroid 
peroxidase (TPO), thyroglobulin (TG), pendrin (causing 
Pendred syndrome [SLC26A4/PDS]), sodium iodide trans-
porter (SLC5A5/NIS), dual oxidase 2 (DUOX2), dual oxidase 
maturation factor (DUOXA2) and iodotyrosine deiodinase 
(IYD) [3].





which is required for the synthesis of thyroid hormones. 
Variants in the DUOX2 gene may result in transient or per-
manent dyshormonogenesis [3].
The TSH receptor (TSHR) gene codes for the TSH- 
receptor, which is a transmembrane protein binding 
TSH and consequently stimulating thyroid hormone 
production. Its variant causes TSH resistance resulting 
in increased TSH levels in an effort to maintain normal 
thyroid hormone secretion, which is not always achieva-
ble. TSHR pathogenic variants cause variable phenotypes, 
ranging from asymptomatic to severe hyper or hypo-
thyroidism. Carriers of inactivating biallelic TSHR gene 
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variants are likely to be identified by neonatal screening, 
whereas those with autosomal dominant-inherited mono-
allelic variants appear in milder forms and may be missed 
in the screening [4, 5].
Herein, we present a boy with mild CH due to double 
variants in the TSHR and DUOX2 gene.
Case report
The patient was born of non-consanguineous parents 
at term, his body weight was 3370 g (P50), and his birth 
length was 50  cm (P50). Pregnancy and spontaneous 
vaginal delivery were uneventful. In the newborn screen-
ing on the 10th postnatal day, serum TSH concentration 
was elevated (79.1 mU/L [normal range: 0.1–10.5]). In the 
recall test after a few days, the TSH level was 222 mU/L and 
free thyroxine (fT
4
) was decreased (0.27 ng/dL [0.8–2.31]). 
Thyroglobulin (Tg) was massively increased (980 µg/mL 
[<75 µg/mL]). At this point, treatment with L-thyroxine 
was started with a dose of 25 µg/day. Five days later, 
the dose was increased to 50 µg/day. Further evaluation 
revealed thyroid peroxidase, Tg and TSH receptor antibod-
ies within the normal range. Ultrasound was performed 
during a  follow-up visit 4  weeks after birth, showing a 
homogenous thyroid gland loco classico with a longitudi-
nal dimension of 15 mm and each lobe having a width of 
7 mm. Family history was unremarkable for thyroid prob-
lems except for the maternal grandmother, who devel-
oped hypothyroidism after menopause. All these findings 
suggested a likely diagnosis of TDH. A perchlorate test to 
distinguish from a thyroid dysgenesis was not performed.
At the age of 2  years, the patient’s thyroid function 
was reevaluated after cessation of L-thyroxine (50 µg) 
substitution 4  weeks earlier. Scintigraphy with 4MBq 
123Jcd revealed homogenous accumulation of the radio-
nuclide in a correctly located thyroid gland.
After discontinuation of thyroid hormone replace-
ment, TSH concentration increased and remained slightly 
elevated (Figure 1), whereas fT
4
 was always within normal 
limits. At this time, the patient showed no symptoms. 
Therefore, therapy was not restarted as subclinical hypo-
thyroidism should not be treated unless there are signs or 
symptoms of hypothyroidism [6].
The patient remained untreated until the age of 
6 years when complaints of fatigue and dry skin appeared. 
At presentation, the patient was clinically examined and 
showed no signs of infection, so no blood test for infec-
tion parameters was done. As a differential diagnosis for 
fatigue, serology tests for celiac disease were done with 
negative results.
As TSH levels were also increasing, L-thyroxine 
replacement was restarted with a dose of 12.5 µg/day. At 
the time of treatment reinstitution, the patient’s height 
was 119.4  cm (P 50, +0.05  standard deviation [SD]), 
weight was 24.5 kg (P 75, +0.84 SD) and body mass index 
(BMI) was 17.2 kg/m2 (P 75–90; z-score +1.2 SD). Thus, the 
patient was not overweight.
During follow-up, TSH levels remained stable within 
the normal range, fatigue disappeared and L-thyroxine 
therapy was continued with a dose of 25 µg/day until 
adulthood when the patient was transitioned to adult 
endocrinology.
Materials and methods
To analyze the patient’s DNA, a custom-designed Illumina sequenc-
ing panel containing genes involved in thyroid dysgenesis (FOXE1, 
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Figure 1: Course of TSH concentration over time.
The dose per kilogram of L-thyroxine on the first episode of therapy ranged from 3 µg/kg to 10 µg/kg. At restart of therapy, the dose was 
approximately 0.3–0.5 µg/kg/day. Current dose is 0.37 µg/kg/day.
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NKX2-1, NKX2-5, PAX8 and TSHR) and dyshormonogenesis (DUOX2, 
DUOXA2, IYD, SLC5A5/NIS, SLC26A4/PDS, TG and TPO) was used. 
Library preparation was performed according to the standard pro-
tocol (Nextera rapid capture custom enrichment kit, Illumina, 
San Diego, CA, USA), followed by sequencing on the MiSeq sequenc-
ing platform (Illumina, San Diego, CA, USA). Sequencing data were 
analyzed using the software Variant Studio (Illumina, San Diego, CA, 
USA) and SequencePilot (JSI medical systems, Ettenheim, Germany). 
Variants of interest were confirmed by Sanger sequencing.
Ethical statement
Informed consent was obtained from all individuals included in 
this study. The research related to human use complied with all the 
relevant national regulations and institutional policies, and was in 
accordance with the tenets of the Helsinki Declaration, and has been 
approved by the authors’ Institutional Review Board or equivalent 
committee.
Results
The patient is heterozygous for two variants in the genes 
DUOX2 and TSHR with a known phenotype of TDH. In 
DUOX2, the sequence variant c.602dupG was identified. 
One base pair is duplicated with the molecular conse-
quence of a frameshift (p.[Gln202ThrfsTer99]). In the 
ClinVar database, it is described as pathogenic/likely 
pathogenic for dyshormonogenesis [7, 8].
In the exon 1 of the TSHR gene, the sequence variant 
c.122G > C has been identified. A guanine replaces cysteine 
which results in an amino acid exchange from cysteine to 
serine (p.[Cys41Ser]). This variant is asserted to be patho-
genic for CH [9].
In both the genes, there was no evidence of a second 
pathogenic sequence variant. No gene dose analysis was 
implemented. The patient is a heterozygous carrier of the 
DUOX2 sequence variant associated with mild hypothy-
roidism and the TSHR sequence variant associated with 
a TSH resistance.
Discussion
According to the consensus guidelines of the European 
Society for Paediatric Endocrinology, transient hypothy-
roidism is defined as elevated TSH levels in the first days 
of a newborn with normalized values after a period of no 
treatment [10]. After the off-treatment period, the patient 
had increased TSH values slightly over the range which 
would fit the definition of transient hypothyroidism. Yet 
our patient needed a restart of therapy, and the symptoms 
of fatigue disappeared after retreatment. Therefore, it 
is difficult to definitively settle whether our patient had 
 transient hypothyroidism.
CH has recently been shown to occur not only as 
monogenic but also as an oligogenic disease, especially 
in patients with eutopic thyroid gland [11]. Our patient 
carries two gene variants, one in the TSHR gene and one 
in the DUOX2 gene, both being previously associated with 
CH. If only one of these genes is mutated, reported pheno-
types are variable and also depend on whether both or one 
allele is affected. If only one allele is mutated, symptoms 
are usually mild and hypothyroidism may be transient or 
mild. Such an observation has been made for both, DUOX2 
variants [12] and TSHR variants [5, 13]. However, correla-
tion between genotypes and phenotypes may be more 
complex as biallelic DUOX2 variants also presented with 
only moderate clinical signs of hypothyroidism.
In the literature, 10 cases with double heterozygous 
variants of the TSHR and DUOX2 genes similar to our 
patient have been reported with available clinical data 
and are reviewed in Table 1 [4, 13–15]. Additional cases 
with double mutations have been published but are not 
included in the table as clinical data were not available 
[16–19].
The presence of an additional monoallelic DUOX2 
variant in a newborn with a monoallelic TSHR variant 
makes a positive result in the newborn TSH screening 10 
times more probable compared to carriers with a TSHR 
variant alone. Along this line, the frequency of double 
heterozygosity in patients with CH was reported to be 
much higher than in the general population in Japan [4]. 
Accordingly, only three out of 11 patients presented in 
Table 1 revealed no or only slightly elevated TSH values 
in the confirmative blood sample after newborn screening 
(upper cutoff value of 10.5 mU/L). All other cases showed 
strongly elevated TSH values and very low fT
4
 levels, 
resulting in immediate L-thyroxine replacement. Only four 
of the latter patients had to continue thyroxine therapy 
after re-evaluation, whereas the other four showed stable 
TSH levels in the upper range, similar to our patient. Thus, 
the genotype alone does not seem to predict the clinical 
follow-up and the need for replacement therapy.
Thyroid size was reduced in the majority of reviewed 
patients fitting more to TSHR sequence variants than to 
DUOX2 variants. Unfortunately, TG concentration was 
reported in only one of the reviewed patients. Like in our 
patient, it was increased. It would be interesting to know 
whether Tg concentration was also elevated in the other 
patients.
Watching the variations, it seems that p.R450H in 
TSHR is a frequent variant in combination with a DUOX2 
Bereitgestellt von | provisional account
Unangemeldet
Heruntergeladen am | 09.01.20 10:00
1302      Sasivari et al.: Dyshormonogenesis due to double variants
variant. But this TSHR allele variant has also been dem-
onstrated to be a common variant in the Japanese and 
Taiwanese population, independent of an additional 
pathogenic variant [13].
In conclusion, our data demonstrate higher probabil-
ity for CH in patients with double heterozygosity for TSHR 
and DUOX2. However, the necessity of continuous thyroid 
replacement is difficult to predict despite good genotype-
phenotype correlation.
Established facts and learning 
points
Established facts
 – Carriers of inactivating biallelic TSHR gene vari-
ants are likely to be identified by neonatal screen-
ing, whereas those with monoallelic variants may be 
missed in the screening [4, 5].
 – DUOX2 pathogenic variants can cause transient or 
permanent hypothyroidism [12].
 – The coexistence of DUOX2 and TSHR variants leads to 
a higher probability of CH [4].
Learning points
 – We report the first case with this combination of path-
ogenic variants of DUOX2 and TSHR with long-term 
clinical follow-up.
 – Patients with variants of TSHR and DUOX2 show dif-
ferences in phenotype despite the same genotype.
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